| First Author | Symonds ALJ | Year | 2023 |
| Journal | Cancer Immunol Immunother | Volume | 72 |
| Issue | 5 | Pages | 1139-1151 |
| PubMed ID | 36342511 | Mgi Jnum | J:346621 |
| Mgi Id | MGI:7617185 | Doi | 10.1007/s00262-022-03319-w |
| Citation | Symonds ALJ, et al. (2023) Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cells. Cancer Immunol Immunother 72(5):1139-1151 |
| abstractText | Although T cells can develop into an exhausted state in the tumour microenvironment, tumour infiltrating T cells (TILs) are important to control tumour growth. By analysing single cell RNA-sequencing data from human tumours, we found that the transcription factors Early Growth Response 2 (EGR2) and 3 were highly induced in TILs, but not peripheral CD8 + T cells, in multiple patient cohorts. We found that deficiency of Egr2 and 3 in T cells resulted in enhanced tumour growth and fewer TILs in mouse models. Egr2 is highly expressed together with checkpoint molecules in a proportion of CD8 + TILs and Egr2high cells exhibit better survival and proliferation than Egr2(-/-)Egr3(-/-) and Egr2low TILs. Anti-PD-1 treatment increases Egr2 expression in CD8 + TILs and reduces tumour growth, while anti-PD-1 efficacy is abrogated in the absence of Egr2 and 3. Thus, Egr2 and 3 are important for maintaining anti-tumour responses of exhausted CD8 + TILs. |
